AimTo compare three different test methods monitoring the situation of inhibited platelet function in patients with acute cerebral infarction taking aspirin orally by establishing receiver operating characteristic (ROC) curve models, and to provide guidance for individual antiplatelet therapy.MethodsFrom February 2010 to October 2011, 127 patients with acute cerebral infarction not taking antiplatelet agents before were enrolled.The rate of CD62P expression was detected with flow cytometry (FCM), urinary 11-dehydro-thromboxane B2 levels was determined quantitatively with ELISA, the AA induced platelet inhibition rate was performed with thrombelastography (TEG) before and after 7-day treatment with aspirin orally.The sensitivity, specificity, and the area under the ROC curve (AUROC) of the three methods were calculated to evaluate their effects.ResultsCD62P expression rate, urine 11-dehydro-thromboxane B2 levels and platelet aggregation rate were significantly declined after treatment in aspirin group, and the differences were statistically significant (p<0.01).After treatment CD62P, urine 11-dehydro-thromboxane B2 levels and AA-induced TEG, had a certain correlation.The sensitivity, specificity and AUROC of the three methods were as follows: CD62P 86.7%, 79.8% and 0.805；11-DH-TXB2 78.5%, 64.7% and 0.767；TEG-AA 81.7%, 87.3%and 0.984.ConclusionsTEG has a high clinical value on monitoring the efficacy of aspirin in patients with acute cerebral infarction, which can provide more individualized guidance for antiplatelet treatment.